Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Neurosense Therapeutics Ltd's Competitiveness

Name: Neurosense Therapeutics Ltd Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Neurosense Therapeutics Ltd (NRSN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NRSN/competitors

https://api.csimarket.com/api/v1/companies/NRSN/relationships

https://api.csimarket.com/api/v1/companies/NRSN/similar

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Business Relationships API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Neurosense Therapeutics Ltd's Competitor Quality Breadth

Group definitions: see Methodology: Performance Group Definitions.

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Neurosense Therapeutics Ltd	-	-	-	Yes
High-Confidence Competitors (9)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

NRSN Stock Performance relative to its Competitors

NRSN Competitors (weighted) Percent change over the selected range

Neurosense Therapeutics Ltd's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(5 of 8)

Similar-Size
(0 of 5)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Neurosense Therapeutics Ltd	-	-
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (8)	40.4%	63.2%
Similar-Size Competitors (5)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Neurosense Therapeutics Ltd's competitor groups requires a Commercial License.

Unlock Full Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

NRSN Stock Performance relative to High-Confidence Competitors

NRSN High-Confidence Competitors (equal-weighted, 10) Percent change over the selected range

NRSN Stock Performance relative to Similar-Size Competitors

NRSN Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Neurosense Therapeutics Ltd's Comment on Competition and Industry Peers

The company operates in the biopharmaceutical industry, which is characterized by rapid technological change and significant competition. Potential competitors include large, experienced companies with substantial financial resources, research and development capabilities, manufacturing capacity, personnel, marketing expertise, brand recognition, and regulatory approval experience. These competitors may develop new drugs or seek approval for existing drugs targeting the same indications as the company. The company is aware of other entities developing potentially disease-modifying therapeutics for Amyotrophic Lateral Sclerosis (ALS).

Competitor data is not yet available for Neurosense Therapeutics Ltd.

Neurosense Therapeutics Ltd's Competitors Named by the Company

Competitive relationships identified from Neurosense Therapeutics Ltd reports and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Coya Therapeutics Inc	Company report	85%	2022 to 2026	3
Genentech	Company report	85%	2022 to 2026	3
Takeda	Company report	85%	2022 to 2026	3
Prevail	Company report	85%	2022 to 2026	3
Eli Lilly	Company report	85%	2022 to 2026	3
Prothena	Company report	85%	2022 to 2026	3
AstraZeneca	Company report	85%	2022 to 2026	3
Prevail/Eli Lilly	Company report	85%	2022 to 2026	3
Amylyx Pharmaceuticals Inc.	Company report	85%	2022 to 2026	3
Biogen Inc.	Company report	85%	2022 to 2026	3
Prilenia Therapeutics B.V	Company report	85%	2022 to 2026	3
Apellis Pharmaceuticals	Company report	85%	2022 to 2026	3
AB Science SA	Company report	85%	2022 to 2026	3

Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Neurosense Therapeutics Ltd's named competitors require a Commercial License.

Unlock Full Access

Methodology: see Methodology: Peer & Competitor Identification, Sourcing.